Non-anthracycline Adjuvant regimens in N(-) Early Breast Cancer. Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center

Similar documents
Non-anthracycline Adjuvant regimens in Early Breast Cancer. Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center

Considerations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology

Evolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology

Non-Anthracycline Adjuvant Therapy: When to Use?

Adjuvant Chemotherapy + Trastuzumab

Nadia Harbeck Breast Center University of Cologne, Germany

Adjuvant Chemotherapy TNBC & HER2 Subtype

OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx

Neo- & A CTx for EBC. Yeesoo Chae, MD, PhD Oncology, Kyungpook National University Hospital, Daegu, Korea

Evolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino

Postoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital

Breast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital

DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA

Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer

SANDRA M. SWAIN. Washington Cancer Institute, Washington, District of Columbia, USA

Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA

Adjuvant chemotherapy in older breast cancer patients: how to decide?

SANDRA M. SWAIN. Washington Cancer Institute, Washington, District of Columbia, USA

Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon

Review Recent advances in systemic therapy Advances in adjuvant systemic chemotherapy of early breast cancer Sara López-Tarruella and Miguel Martín

30 TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) NEW ADVANCES IN THE TREATMENT OF BREAST CANCER

Toxicities of Chemotherapy Regimens used in Early Breast Cancer

Treatment of Early-Stage HER2+ Breast Cancer

Systemic Therapy of HER2-positive Breast Cancer

Early Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center

Anthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial

Anthracyclines in the elderly breast cancer patients

Treatment of HER-2 positive breast cancer

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer

Ideal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria

新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方

PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center

Novel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center

Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint

Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland

Locally Advanced Breast Cancer: Systemic and Local Therapy

2

Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016

Adjuvant Endocrine Therapy: How Long is Long Enough?

Use of Taxanes in Older Breast Cancer Patients

Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012

Best of San Antonio 2008

ASCO and San Antonio Updates

NeoadjuvantTreatment In BC When, How, Who?

Clinical Expert Submission Template

PIO Treffen Berlin Mammacarcinom

Treatment of Early Stage HER2-positive Breast Cancer (One size does not fit all)

Do we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD

HER2-positive Breast Cancer

The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?

Adjuvant Systemic Therapies in Breast Cancer

St Gallen 2017 controversies & consensus

St. Gallen ASCO Carlos H. Barrios, MD

Systemic Therapy of HER2-positive Breast Cancer

The Three Ages of Systemic Adjuvant Therapy for EBC

Early and locally advanced breast cancer: diagnosis and management

Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016

Extended Hormonal Therapy

Triple Negative Breast cancer New treatment options arenowhere?

Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance

Triple Negative Breast Cancer: Part 2 A Medical Update

Common disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,

Harmesh Naik, MD. Hope Cancer Clinic

亞東紀念醫院 Breast Cancer 化學治療處方集

Breast Cancer: Chemotherapy and Novel Agents

William J. Gradishar MD

Sesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015

Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011

Systemic Therapy for Locally Advanced Breast Cancer

Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy

BREAST CANCER Adjuvant Therapy

Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives

Adjuvan Chemotherapy in Breast Cancer

(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC

Breast : ASCO Abstracts for Review

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

COME HOME Innovative Oncology Business Solutions, Inc.

BREAST CANCER RISK REDUCTION (PREVENTION)

What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland

Endocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology

8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview

NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium

III Congreso Internacional de Oncologia del Interior XII Jornadas de Oncologia del Interior Cordoba Argentina. Farmacogenomica y Cancer de Mama

Adjuvant Systemic Therapy in Early Stage Breast Cancer

Appendix Four. Clinical effectiveness. Contents

Geriatric Oncology Breast Cancer

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

IntensifiedCT with stemcellrescue for high-riskprimary breastcancer

Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer

Disclosures. Objectives. Novel Agents in the Systemic Management of Breast Cancer (Breast Cancer Update 2012) Peter Kabos, MD

Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology

The Expert Thoughts. Alessandra Fabi Oncologia Medica 1

Welcome and Introduction. Miguel Martin Spain

ASCO 2017 BREAST CANCER HIGHLIGHTS

ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Key Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines

Adjuvant chemotherapy of breast cancer

Transcription:

Non-anthracycline Adjuvant regimens in N(-) Early Breast Cancer Yeesoo Chae, MD, PhD Medical Oncology Kyungpook National University Medical Center

Case: Clinical history F/45, Premenopause C/C: Rt. Palpable breast mass P/I Rt. Palpable breast mass ct1cn0m0 (2cm) Medical History: No underlying disease In Hospital course (I) 2008.11.27 Rt. PM with SLND IDC, pt1cn0mim0, G3, LVI(-), ER/PgR/HER2/Ki67 8/6/1/24%

Q1: What is your decision for systemic adjuvant chemotherapy F/45, Premenopause C/C: Rt. Palpable breast mass P/I Rt. Palpable breast mass ct1cn0m0 (2cm) Medical History: No underlying disease In Hospital course (I) 2008.11.27 Rt. PM with SLND IDC, pt1cn0mim0, G3, LVI(-), ER/PgR/HER2/Ki67 8/6/1/24%

What should we consider for adjuvant treatment? Clinico-pathologic factors: Node, Size, Grade, LVI ER/PgR HER2 Ki67 Gene Signature OncotypeDX MammaPrint PAM50 Age & comorbidity Side effects: acute and late

N- breast cancer: Incidence of the world (2010) 50% of all newly diagnosed Oncologist. 2011

International guidelines: Adjuvant chemotherapy for N- EBC Stage I breast cancer has increased dramatically Only 15% in 1990 s Up to 50% of all EBC New guidelines suggest active chemotherapy for small tumor based on subtype St Gallen 2013 Luminal A Luminal B Luminal B /HER2 - /HER2 + HER2 enrich TNBC T1a - +/- + + + T1b ( 5mm) - +/- + + + T1c - +/- + + + T2 - + + + + Node + 1 3 +/- >3 + + + + + NCCN guidelines ER +/HER2 - ER +/HER2 + HER2 enrich TNBC T1a - - - - T1b ( 5mm) RS +/- +/- +/- T1c + + + + T2 + + + + Node + + + + + patients with small tumor have NOT been included for adjuvant CTx trials

Adjuvant Chemotherapy for T1N0 tumor : NCCN Prospective cohort study: 4,113 with T1a,bN0M0 among 24,931 EBC Pts during 2000-2009 Median F/U of 5.5yr Ines Vaz-Luis et al. JCO 2014 &ASCO2014 abstract #522

= RCTs for Adjuvant chemotherapy: T+A>A based CMF CMF6 NSABP B-15 NSABP B-23 AC6 CALGB40101 E2197 NSABP B-30 = AC4 = AT4 = TAC4 FACS05 CEF/FEC MA5 CAF/FAC NSABP B28 NSABP B27 PACS01 TACT GEICAM2003-02 GEICAM9906 GEICAM9805 BCIRG001 NSABP B30 NCIC MA.21 ECOG1199 FEC T or P FAC wp TAC6 = AC4 T AC4 P AC4 wp12 ECOG1199 CALGB 9741 ddac4 ddp

Adjuvant chemotherapy with taxane EBCTCG Lancet 2012: Taxane-containing regimens as standard for N+ De Laurentiis et al, JCO2008: adding taxane improves DFS & OS absolute 5-yr benefit: 5% for DFS and 3% of OS Similar efficacy regardless of type of taxane, ER status, N1-3

Adjuvant chemotherapy with taxane for N(-) EBC EBCTCG Lancet 2012: Taxane-containing regimens as standard for N+ EBCTCG Lancet 2012

Clinical trials for N- EBC Trial period N N % mf/u regimens Trial period N N % MDACC Anglo- Celtic FinHER NSABP B-27 ECOG 2197 USO 9735 TACT NCIC MA.21 1994 1998 1999 2001 2000 2003 1995 2000 1998 2000 1997 2000 2001 2003 2000 2005 524 38 60 P FAC v FAC ECTO 363 34 80 1,010 11 36 AD S v AC S D FEC v V FEC 2,411 70 102 S AC D v S AC ECOG 1199 USO Loesch 1996 2002 1999-2002 2000-2002 1,355 54 76 4,950 12 64 mf/ U regimens S AP CMF S A CMF AC P3 v P1 AC P3 v D3 AC P3 v D1 1,830 73 60 AP P1 v AC P3 2,778 66 80 AD v AC tango1 2000-3,152 23 35 EC GP v EC P 1,016 48 83 DC v AC FinXX 4,162 20 52 2,104 22 30 FEC D v FEC or E CMF AC P v CEF AC P v ddec6 P GEICAM 9805 GEICAM 2003 2004-2007 1999 2003 2003-2008 1,500 10 59 DX CEX v D CEF 1,059 100 72 DAC v FAC 1,925 100 63.3 FAC wp v. FAC

Adjuvant chemotherapy: T+A for N-EBC 2 RCTs only for N- EBC GEICAM9805 GEICAM2003-02 1 meta-analysis Jacquin et al. BCRT 2012

RCT1: TAC vs. FAC for node-negative GEICAM9805 EBC, R0 resected N0, high risk* (N=1060) 1:1 TAC#6 + Prophyl Antibiotics+GCSF** FAC#6 Primary end points: DFS Key secondary end points: OS *Tumor size >2 cm, ER/PR -/-, tumor histologic grade 2 or 3, or age <35 ys **amended d/t high incidence of NF Martin M et al, NEJM 2010

GEICAM9805: TAC vs. FAC Median F/U 77 months 90.1% 85.3% Δ6% Δ2% 87.8% 95.2% 81.8% 93.5% DFS: HR=0.68 (0.49-0.93); p=0.01 OS: HR=0.76 (0.45-1.26); p=0.29 Martin M et al, NEJM 2010

GEICAM9805: Discussion High % of premenopause and younger aged Higher toxicity related with TAC Efficacy related with locoregional control than distant local regional distant TAC FAC P G3,4 28.2% 17.0% P<0.001 SAE 22.4% 4.2% Discontinuation 4.7% 0.8% TRM 0 0 6.3% 0.7% TAC 7.3% 0.8% 3.3% FAC Martin M et al, NEJM 2010

RCT2: GEICAM/2003-02: FAC-wP v. FAC Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. EBC, R0 resected T1-3, N0, high risk* (N=1925) 1:1 FAC#4 wp#8 FAC#6 Primary end points: DFS Key secondary end points: OS *Tumor size >2 cm, ER/PR -/-, tumor histologic grade 2 or 3, or age <35 ys Martin M et al, JCO 2013

GEICAM/2003-02: FAC-wP v. FAC Median F/U 63.3months Martin M et al, JCO 2013

Metaanalysis: T+A or T for N-EBC Study Node N HER2 T Non-T F/U GEICAM 9805, Martin N-/+ 1060 64% TAC FAC 5 ECOG 2197, Goldstein N-/+ 1893/989 No AT AC 5 USO 9735, Jones N-/+ 487/529 17% TC AC 7 UK TACT, Ellis N-/+ 835/3327 86% FEC-T FEC or E-CMF 5 RAPP-01, Brain N-/+ 627 No AT AC 5 FinHer, Joensuu N-/+ 1010 89% T-FEC V-FEC 5 BCIRG001, Martin N+ 1491 85% TAC FAC 4.5 TAXIT 216, Cognetti N+ 972 No E-T-CMF E-CMF 5 PACS01, Roché N+ 1999 No FEC-T FEC 5 BIG2-98, TAX315, N+ 2887 No A-T-CMF or AT-CMF A-CMF or AC-CMF 5 WSG/AGO, Nitz N+ 3 1837 Yes EC-T FEC 5 HORG, Polyzos N+ 756 39% T-EC FEC 5 PACS-04, Roché N+ 3010 Yes ET FEC 5 ADEBAR, Janni N+ 3 1502 Yes EC-T FEC 4 14 P-III RCTs (N=25,067) N0 (N=4,274) Jacquin et al. BCRT 2012

Metaanalysis: T+A or T for N-EBC Jacquin et al. BCRT 2012

Which regimen for N- EBC? Taxane + Anthracycline 2 RCTs for N- EBC showed better PFS, but No OS benefit Minimal efficacy: Only 5 % for PFS and <3% for OS Higher toxicity rate with A+T Meta-analysis of 14 RCT including N- EBC patients Adding taxane seems better in DFS

Anthracycline vs. CHF cardiotoxicity ass. with anthracyclines Cumulative dose of Anthracycline: 400-450mg/m 2 Doxorubicin Epirubicin Praga C et al, Clinical Measurement In Drug Evaluation 1991

A-induced cardiotoxicity 300mg/m 2 of Anthracycline (FAC) seemed safe A related cardiotoxicity can occur less than 300mg/m 2 Late onset was NOT rare the 10-y follow-up of the BCIRG001 trial FAC is associated with an unexpectedly high cardiac toxicity. 17 (2.3%) CHF and four (0.5%) deaths LVEF drop > 20% in 41 (15%) Martin M et al, SabCS2010; Shulman LN et al JCO2012; Ryberg et al, JNCI 2008

A-related Cardiotoxicity in non-trial population true toxicity in the non-trial population. Observatory study by Giordano et al JCO 2006 19 vs. 14% Δ5% 47 vs. 33% Δ14% Giordano et al JCO 2006

Toxicities of Anthracyclines Risk of cardiotoxicity: 6-26% High emetogenic agent High proportion of young female in Korea Much more intolerant to Anthracyclines d/t Nausea Vesicant infertility Risk of leukemia ~0.5%

Adjuvant chemotherapy for N- EBC Usually good outcome with standard treatment 5y-DFS of 85-90% or more 5y-OS of 95% or more Adding taxane into A-based regimen: Yes, but small efficacy (3-6% gain in DFS; 2% gain in OS) Higher rate of toxicity: G3-4 hematologic toxicity, neuropathy, edema, Taxane without A in low-risk group? TC TCH for HER2+

USO 9735 study: TC vs. AC Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: Stage I, II, or III 71% ER 48% LN negative Stratification factors: Age, Nodal status R 4 x TC q3w Docetaxel (75 mg/m 2 ) Cyclophosphamide (600 mg/m 2 ) 4 x AC q3w Doxorubicin (60 mg/m 2 ) Cyclophosphamide (600 mg/m 2 ) Tamoxifen was given to all ER+ patients Median follow up: 5.5 ys Primary Objective : Disease-free survival (DFS) Secondary Objective : Overall survival (OS), Safety Jones SE et al. J Clin. Oncol 2009

USO 9735 study: TC vs. AC in low risk group TC (n=506) AC (n=510) Median Age, ys (range) 52 (27-77) 51(27-77) Stage (%) I II III Unknown HR status (%) ER /PR(+/+,-/+,+/-) ER-/PR- Unknown Positive nodes (%) 0 1-3 4 104 (20) 373 (74) 27 (5) 2 (1) 367 (72) 136 (27) 2 (1) 239 (47) 209 (41) 58 (12) 112 (22) 364 (71) 34 (7) 0 (0) 352 (69) 157 (31) 1 (<1) 248 (49) 212 (42) 50 (9) Jones SE et al. J Clin. Oncol 2009

USO 9735 study: TC is superior regardless of N or Age Δ3% 89% 86% HR 0.74; 95% CI, 0.56-0.98 P = 0.033 81% 75% Δ6% Δ1% 94% 93% HR 0.69; 95% CI, 0.50-0.97 P = 0.032 87% 82% Δ5% 1. Jones SE et al. J Clin Oncol 2006;274:5381-5387 2. Jones SE et al. J Clin Oncol 2009;27:1177-1183

USO 9735: Toxicity All grade G3,4: N/V, stomatitis 100% 80% TC (docetaxel / cyclophosphamide) AC (doxorubicin / cyclophosphamide) 100% 80% 60% 60% 40% 40% 20% 20% 0% 0% 3 fatal events (CHF, MDS, MF) were found in AC arm Jones et al. J Clin Oncol. 2006;24:5381-5387.

USO 9735: Conclusion At 7 ys, 4 cycles of TC compared to AC was associated with Superior DFS (P = 0.033) and Overall Survival (P = 0.032) TC was effective in older as well as younger patients TC may have same efficacy in N(-) EBC TC was equally effective in ER+ disease as well as HR-disease Less side effects and long term sequelae TC regimen is optimal treatment for low-risk breast cancer patients as alternative to anthracycline based adjuvant therapy

TC vs EC T for HER2- EBC PlanB: P-III Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative EBC NCT01049425 HER2 Negative Breast Cancer (n=2,448) 2010.1~2014.8 R0 resected T1-4 HER2- N+ or high risk N-* + 1º End point: DFS *tumor size > or = 2 cm, grade > or = 2, ER and PR negative, high upa//pai-1 levels www.clinicaltrials.gov

HER2+/N- EBC for small N-/HER2 EBC Trastuzumab into CT, mostly A+T Persistent effect on RFS and OS Mostly stage II or III were rerolled in RCTs 6% N-/HER2+ in N9831+NSABP B31 Study Patient population N ER+, % N-,% pt1, % HR for DFS (95% CI) HR for OS (95% CI) N+ 0.54 (0.43 0.67) HERA N, >pt1b 3387 45 32 40 N-: 0.51 (0.30 0.87) pt1c: 0.59 (0.39 0.88) 0.76 (0.47 1.23) Intergroup N9831, NSABP- B31 N+ N, pt1c ER+ N, pt1b ER 3969 52 6 39 0.49 (0.41 0.58) 0.62 (0.49 0.81) BCIRG 006 N+ N & risk factors c 3222 54 29 40 0.49 (ACTH), 0.61 (TCH) N-: 0.32 (0.17 0.62) pt1c : 0.6 (0.4 1.0) ACTH:0.63 (0.48 0.81) TCH:0.77 (0.60 0.99) PACS-04 N+ 3010 18 None 32 0.86 (0.61 1.22) 1.27 (0.68 2.38)

HER2+/N- EBC for small N-/HER2 EBC Trastuzumab into CT, mostly A+T Persistent effect on RFS and OS Mostly stage II or III were enrolled in RCTs 6% N-/HER2+ in N9831+NSABP B31 T1N0 HER2+: Unfavorable outcome without CT 7% of cumulative incidence of relapse at 5 years

HER2+/N- EBC for small N-/HER2 EBC Trastuzumab into CT, mostly A+T Persistent effect on RFS and OS Mostly stage II or III were rerolled in RCTs 6% N-/HER2+ in N9831+NSABP B31 T1N0 HER2+: Unfavorable outcome without CT CT+trastuzumab can decrease relapse in P-II or cohort studes T1a T1b ER+/HER2+ ER-/HER2+ ER+/HER2+ ER-/HER2+ CT+/-H - + - + - + - + DRFS 96 100 93 100 94 96 94 94 OS 95 100 93 100 95 99 100 95

HER2+/N- EBC for small N-/HER2 EBC Trastuzumab into CT, mostly A+T Persistent effect on RFS and OS Mostly stage II or III were rerolled in RCTs 6% N-/HER2+ in N9831+NSABP B31 T1N0 HER2+: Unfavorable outcome without CT CT+trastuzumab can decrease relapse in P-II or cohort studes St. Gallen & NCCN recommend adjuvant CTx+trastuzumab St Gallen 2013 Luminal A Luminal B/H Luminal B/H HER2 enrich ER2 - ER2 + TNBC T1a - +/- + + + T1b ( 5mm) - +/- + + + T1c - +/- + + + NCCN guidelines ER +/HER2 - ER +/HER2 + HER2 enrich TNBC T1a - - - - T1b ( 5mm) RS +/- +/- +/- T1c + + + +

HER2+/N- EBC for small N-/HER2 EBC Trastuzumab into CT, mostly A+T Persistent effect on RFS and OS Mostly stage II or III were rerolled in RCTs 6% N-/HER2+ in N9831+NSABP B31 T1N0 HER2+: Unfavorable outcome without CT CT+trastuzumab can decrease relapse in P-II or cohort studes St. Gallen & NCCN recommend adjuvant CTx+trastuzumab Trastuzumab + Anthracycline as adjuvant therapy Increase the incidence of Cardiac toxicity

HER2+/N- EBC for small N-/HER2 EBC Trastuzumab into CT, mostly A+T Persistent effect on RFS and OS Mostly stage II or III were rerolled in RCTs 6% N-/HER2+ in N9831+NSABP B31 T1N0 HER2+: Unfavorable outcome without CT CT+trastuzumab can decrease relapse in P-II or cohort studes St. Gallen & NCCN recommend adjuvant CTx+trastuzumab Trastuzumab + Anthracycline as adjuvant therapy Increase the incidence of Cardiac toxicity Emesis Less toxic regimen without affecting survival advantage? TCH? In BCIRG006

BCIRG 006: TCH vs. AC TH Adjuvant Trastuzumab in HER2-Positive Breast Cancer 29% N- Primary : DFS Secondary : OS, Safety AC : doxorubicin ab cyclophosphamide,t : docetaxel, H : trastuzumab Slamon D et al. N Engl J Med 2011;365:1273-1283.

% alive and disease-free % alive BCIRG006: TCH vs. AC TH for N- (subanalysis) Unplanned analysis: TCH vs. AC TH 1.0 1.0 Δ1% 0.9 0.8 Δ3% 84% 81% 0.9 0.8 92% 91% 87% 0.7 75% 0.7 0.6 0.5 0.4 Patients Events HR (95% CI) P AC T 1073 257 1 (reference) AC TH 1074 185 0.64 (0.53-0,78) <0.001 TCH 1075 214 0.75 (0.63-0.90) 0.04 0 12 24 36 48 60 72 Time (months) 0.6 0.5 0.4 Patients Events HR (95% CI) P AC T 1073 141 1 (reference) AC TH 1074 94 0.63 (0.48-0,81) <0.001 TCH 1075 113 0.77 (0.60-0.99) 0.038 0 12 24 36 48 60 72 Time (months) Similar efficacy in N- subset.: Δ3% for DFS; Δ1% for OS Slamon D et al. N Engl J Med 2011;365:1273-1283.

BCIRG006: Cardiac safety Cardiac Adverse Event AC T (n = 1073) AC TH (n = 1074) TCH (n = 1075) Cardiac-related death 0 0 0 Grade 3/4 CHF 7 (0.7) 21 (2.0) P < 0.001 4 (0.4) P < 0.001 > 10% relative LVEF decline 114 (11.2) 194 (18.6) 97 (9.4) Slamon D et al. N Engl J Med 2011;365:1273-1283.

BCIRG006: QoL TCH as a more tolerable alternative to anthracyclinetrastuzumab based adjuvant therapies Proportion of patients whose HRQL worsened by at least 10 units Au HJ et al. The Oncologist 2013; 18:812-818

HER2+ EBC: Non-anthracycline regimen Chemotherapy + Trastuzumab significant improvements in OS and PFS Trastuzumab + Anthracycline as adjuvant therapy Significant benefit of Trastuzumab but, remained cardiac problems Stage I breast cancer has increased dramatically Less toxic regimen without affecting survival advantage? TCH as adjuvant P-II 2 & 3 trials of TCH in patients with advanced disease Similar in PFS and OS Better in Safety

Adjuvant chemotherapy for N- EBC Adding taxane into A-based regimen: TAC FAC wp Yes, but small efficacy (3-6% gain in DFS; 2% gain in OS) Higher rate of toxicity: G3-4 hematologic toxicity, neuropathy, edema, NCCN guideline v.2 2015 Taxane without A TC TCH for HER2+ Preferred regimens: HER2 negative ddac ddp ddac wp TC HER2 positive AC TH TCH

Adjuvant chemotherapy for N- EBC Adding taxane into A-based regimen: TAC FAC wp Yes, but small efficacy (3-6% gain in DFS; 2% gain in OS) Higher rate of toxicity: G3-4 hematologic toxicity, neuropathy, edema, Taxane without A TC TCH for HER2+?Taxane only to avoid unexpected treatment related morbidity and mortality.

CALGB40101: AC vs. Paclitaxel AC vs. P Primary Endpoint: PFS, non-inferiority 2002-2010 90% N(-), 84% HER2- Median F/U 6.1 yr 91% 95% Δ3% Δ1% 88% 94% HR, 1.26; 95% CI, 1.05-1.53 HR 1.27; 95% CI, 1.00 to 1.62 non-inferiority of T over AC regardless of HR status Shulman. JCO 2014

CALGB40101: AC vs. Paclitaxel AC4 vs T4 or T6 But small : Δ3% and Δ1% AC: Higher hematologic toxicity and.. AC T Cause of Death (n = 1,931) (n = 1,940) Breast cancer 60 87 TRM 9 0 AML/MDS 7 0 Cardiotoxicity 2 0 Other 47 63 Total 116 150 Taxane without A might be an option in low-risk EBC. Shulman. JCO 2014

Small HER2+ : paclitaxel+ trastuzumab Phase II Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer (NCT00542451) 2007.10~2010.9 DFS = 98.7% at Median F/U at 4.0y T 3cm, N0 HER2+BC N=406 P80 + Trastuzumab weekly x 12 Trastuzumab every 3 weeks x 13 N % T1a T1b T1c T2 (2-3cm) 77 124 169 36 19 31 42 9 91% ER+ ER- 272 134 67 33 Tolaney et al., NEJM 2015; SABCS 2013

Small HER2+ : paclitaxel+ trastuzumab Comparable to T+A+ H regimens 4Y DFS = 98.7% 98.7% Similar outcome regardless of tumor size and HR Tolaney et al., NEJM 2015; SABCS 2013

Randomize 3:1 Small HER2+ : T-DM1 vs. paclitaxel+ trastuzumab Adjuvant for small tumors: Phase II ATEMPT Trial (NCT01853748) Dana-Faber Cancer Institute Stage I HER2+ EBC (T1N0M0) 2013.5 ~ Stage I BC HER2+ N=500 3 1 T-DM1 q 3 weeks x 17 N=375 Paclitaxel + Trastuzumab weekly x 12 Trastuzumab every 3 weeks x 13 N=125 www.clinicaltrials.gov

How did these studies change our practice? NCCN cohort for Adjuvant Chemotherapy for T1N0M0 A) HER2+ B) HER2- HR+ C) HER2- HR- anthracycline TC A+T TCbH Other Ines Vaz-Luis et al. ASCO2014 abstract #522

Adjuvant chemotherapy for N- EBC Adding taxane into A-based regimen: TAC FAC wp Yes, but small efficacy (3-6% gain in DFS; 2% gain in OS) Higher rate of toxicity: G3-4 hematologic toxicity, neuropathy, edema, Taxane without A HER2- HER2+ Non T, Non A CMF? TC T? TCH T +/- Hercetpin? T-DM1?

CMF vs. Anthracyclines No evidence of AC4 > CMF6 Study No. of Pts Population regimen DFS(%) OS(%) NSABP B-15 1557 node (+) AC x 4 62 NS 83 NS CMF x 6 63 82 NSABP B-23 2008 node (-) AC x 4 87 NS 90 NS,ER(-) AC x 4 + Tam 87 90 CMF x 6 88 89 CMF x 6 +Tam 87 89 Belgian 777 node (+) E60Cx 8 64 78 E100Cx 8 74 NS 86 NS CMF x 6 71 65 Fisher B, et al. JCO 1990; 8: 1483-1496. Fisher B, et al. JCO 2001;19: 931-942 Piccart MJ et al. JCO 2001;19(12): 3103-3110

Classic CMF is more effective TNBC: IBCSG VIII+IX IBCSG VIII+IX N=2257 N-EBC CMF6 vs. none HR, 0.46; 95% CI, 0.29 to 0.73; P =.009 Colleoni et al, JCO 2010

CMF vs. weekly docetaxel (Elderly) ELDA trial: Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III 302 Elderly (aged 65 79) Stage I-III 37% N- CMF CMF wd wd Perrone et al. Ann Oncol 2015

CMF: Old but still active Similar outcome with AC4, CAF, w-docetaxel Better than capecitabine (CALGB trial) Better safety profile than TC or AC Still can be an option for N-EBC Elderly or Cardiac concern (+)? Modified or dose-dense Title Phase N Endpoint No Study arms Inclusion ELDA 3 300 DFS NCT00331097 CMF6 v. w-docetaxel 60-80 ICE II III 400 DFS NCT01204437 CMF6 v. EC4 v X-Nab-P >65 Sarah canon research 3 150 DFS NCT00193011 D v CMF >65 UK 3 2000 DFS NCT00003577 CMF6 v E4 CMF4 I,II CALGB 3 633 DFS NCT00024102 X vs AC or CMF >65

Case: In hospital course (II) Plan: Adjuvant AC#4 cycles followed by RT + Hormone (Tam) After 4 cycles of AC, Mild DOE with Anemia (Hb=8.2g/dl) Continued DOE after correction of Anemia C/T=45.9% (pre-op) C/T=65.4% (post-ctx)

Case: In hospital course (II) 2D-Echocardiogram EF=20% imp: severe CHF d/t r/o Anthracycline-induced Cardiac transplantation was done..

Summary: Adjuvant chemotherapy for N- EBC Node negative breast cancer is usually expected for good outcome with standard treatment, T+A as concurrent or sequential TAC FAC wp Yes, but small efficacy (3-6% gain in DFS; 2% gain in OS) Higher rate of toxicity: G3-4 hematologic toxicity, neuropathy, edema, T without A Non T, Non A CMF HER2- TC > AC T? HER2+ TCH = AC TH T +/- Hercetpin? T-DM1?

Thank you for your attention!!! Thirty-one years ago, the original AC regimen was reported. Now, there is a superior nonanthracycline regimen, TC Jones et al, J Clin Oncol